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Abstract
Human cytomegalovirus (hCMV) reactivation may often coincide with the development of
graft-versus-host-disease (GVHD) in stem cell transplantation (SCT). Seventy seven SCT
donor-recipient pairs (DRP) (HLA matched unrelated donor (MUD), n = 50; matched related
donor (MRD), n = 27) underwent whole exome sequencing to identify single nucleotide polymorphisms (SNPs) generating alloreactive peptide libraries for each DRP (9-mer peptideHLA complexes); Human CMV CROSS (Cross-Reactive Open Source Sequence) database was compiled from NCBI; HLA class I binding affinity for each DRPs HLA was calculated by NetMHCpan 2.8 and hCMV- derived 9-mers algorithmically compared to the
alloreactive peptide-HLA complex libraries. Short consecutive (6) amino acid (AA)
sequence homology matching hCMV to recipient peptides was considered for HLA-boundpeptide (IC50<500nM) cross reactivity. Of the 70,686 hCMV 9-mers contained within the
hCMV CROSS database, an average of 29,658 matched the MRD DRP alloreactive peptides and 52,910 matched MUD DRP peptides (p<0.001). In silico analysis revealed multiple
high affinity, immunogenic CMV-Human peptide matches (IC50<500 nM) expressed in
GVHD-affected tissue-specific manner. hCMV+GVHD was found in 18 patients, 13 developing hCMV viremia before GVHD onset. Analysis of patients with GVHD identified potential
cross reactive peptide expression within affected organs. We propose that hCMV peptide
sequence homology with human alloreactive peptides may contribute to the pathophysiology of GVHD.
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sorting based on the screening parameters set for
the HLA-specific peptide binding affinity, IC50<500
nM, using netMHCpan version 2.8. These binding
data were acquired for use in the bioinformatics
pipeline from IEDB as previously described. GVHD
tissue-specific peptide expression data was
obtained from GTEx through third-party public
download for CMV-reactivation cross-sectional
analyses. The predictive binding affinity
classification along with the data from the GeneTissue Expression Database (GTEx) were used to
sort patient data by GVHD-tissue for statistical
correlation and precluded patient alloreactive
peptide library publication in the data repositories,
dbSNP/ClinVar, per their own specifications. All
other previously published alloreactivity data from
the earlier VCU Whole Exome Sequencing Study
MCC-14012 may be available upon request by
contacting: amir.toor@vcuhealth.org.
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Introduction
Human cytomegalovirus and other viral infections pose a significant hurdle to successful stem
cell transplantation, affecting morbidity and mortality rates among the immunocompromised
populations the world over. [1,2] Human CMV seropositivity has been estimated in 50–80% of
the population in the United States by age 40. [3] While the majority of infected patients are
asymptomatic due to viral latency after initial viral clearance, SCT patients with newly reconstituted immune systems exhibit rates of reactivation approximately 30–65% in multiple studies. [4–7] Furthermore, hCMV reactivation often coincides with the incidence of another
serious complication of SCT, i.e., GVHD. [8–11] Although many groups have historically separated GVHD incidence from hCMV infection data, even by complete exclusion in clinical
trial design, there has been growing evidence that these diseases are not mutually exclusive and
are likely linked in a number of ways beyond treatment. [12,13]
GVHD pathophysiology is driven by donor T cell mediated alloreactivity, directed against
recipient mHA. These are recipient-derived oligopeptides presented on HLA molecules, and
result from coding nucleotide sequence variation. Whole exome sequencing has been used
to identify the entire library of nucleotide variation that exists between the exomes of HLA
matched SCT donors and recipients. [14] From these data it is possible to derive, in silico,
all the potential unmodified alloreactive peptides which bind the relevant HLA (class I for
example) in a donor-recipient-pair (DRP), and in turn this metric may be used to estimate a
patient’s given potential to develop alloreactivity, or GVHD. [15] Aside from helping understand GVHD pathophysiology, this library of recipient-derived mHA-HLA complexes may
also be used to interrogate the relationship between pathogen antigens, as well as tumor antigens, and the disease states that may result, in particular the development of cross-reactive illness, such as GVHD triggered by CMV or other viral reactivation.
T cell cross reactivity originally was uncovered in relation to autoimmunity, especially in
the context of CMV [16–19] and solid organ transplantation. [20–23] T cell cross reactivity
occurs because, TCR-peptide-HLA class I bound complexes exhibit a strong recognition of
2–4 central amino acid residues in various orientations and allow for multiple amino acid substitution to the flanks in anchor positions while relying on HLA and peptide sequences simultaneously. The idea of T cells reacting to antigens with amino acid sequence homology (6/6
consecutive AA residues in a 9-mer for example) on different cell types with a given HLA-class
I type has taken hold from multiple clinical examples. [17] Therefore, while CMV and other
B-Herpesviruses have been shown to be associated with autoimmunity and contribute to oncogenic progression possibly affecting relapse rates, [24–26] CMV-specific T cell cross reactivity
through adoptive lymphocyte transfer has been shown effective in the treatment of glioblastoma multiforme upon reactivation. [27,28] These clinical trials centering on confirmed
CMV-specific T cell cross reactivity with infected tumor cells highlights the expectation of
eliciting an immune response to CMV and ‘self’ tumor cells simultaneously. However, the
development of CMV-specific T cells in that manner raises the question of eliciting a crossreactive GVHD response against HLA bound-alloreactive recipient peptides. In theory, this
may occur due to peptide polymorphisms, resulting from single nucleotide polymorphisms
(SNPs). Resulting polymorphic peptides in the recipient with enough sequence homology to
CMV peptides to elicit a HLA-specific immune response, may be presented as targets to donor
lymphocytes (Fig 1).
Therefore, if CMV-derived HLA class I bound oligopeptide have sequence homology with
human, alloreactive peptides bound to the same HLA class I and trigger cross recognition by
donor T cells, the presence of these cross-reactive peptides may constitute a risk factor for the
development of GVHD following SCT. In this study, HLA bound peptide-match analysis is
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Fig 1. Hypothetical CMV—Human antigenic mimicry model. Proposed cross-reactivity model for CMV-specific T cells that may react to matched
homologous peptides (6/6 consecutive amino acids) bound to the same HLA on normal recipient cells present in GVHD-affected tissues.
https://doi.org/10.1371/journal.pone.0178763.g001

facilitated by a newly compiled Human CMV CROSS (Cross-Reactivity Open Source
Sequence) database. There were CMV—human peptide sequence matches present, and in a
majority of CMV sero-positive patients with GVHD, this was corroborated by GVHD-specific
organ incidence of the human peptide source genes.

Methods
Whole exome sequencing and peptide library creation
Patients with recurrent or high-risk hematological malignancies undergoing allogeneic SCT at
Virginia Commonwealth University were included in this retrospective study following Virginia Commonwealth University (VCU) Institutional Review Board approval, MCC-14012
Study. VCU IRB waived the need for informed consent to MCC-14012 on all adult participant
archived samples, de-identified by clinical research staff. The demographic and clinical data
were not available to the exome sequencing team, and exome sequencing data was not available to the research team, with the exception of SNP identity in a donor recipient specific manner. Exome sequencing data are maintained on secure server with the VCU Center for the
Study of Biological Complexity. Previously cryopreserved DNA samples were whole exome
sequenced following de-identification by the BMT research team. These recipients received an
allograft from either a related or an unrelated, HLA-matched donor at 8/8 or 7/8 HLA loci S1
Table. There were no significant differences in the HLA-matched and HLA-mismatched
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related and unrelated donors, therefore these were considered together. The transplant DRP,
were annotated for identification of all the non-synonymous single nucleotide polymorphisms
(nsSNPs), across the whole exome, in the graft versus host (GVH) direction (nsSNP(GVH)),
i.e., polymorphism present in the recipient but absent in the donor. [14] Each nsSNP(GVH)
was analyzed using the ANNOVAR software, [29] as previously described, [15] to populate the
flanking amino acids around each amino acid coded for by each of the polymorphisms. This
was accomplished through sequence padding, using DB SNP130 and hg18 genome coordinates, and yielded 17-mer peptides with variant amino acids occupying the central location.
This 17-mer oligopeptide library created the opportunity to derive 9 separate 9-mer recipient
oligopeptides, using a sliding window method, with the polymorphism-derived amino acid
positioned at position 1–9 from C- to N-terminus. The nine oligopeptides generated per
nsSNP(GVH) were extended to the whole exome for each recipient, representing each DRPs’
unique peptide library.

In silico peptide-HLA binding affinity determination
Patient peptide libraries were initially analyzed by the NetMHCpan software, version 2.8.
[30,31] The analytic output yielded source gene information, polymorphic peptide sequence
(9-mer), and a calculated IC50 value from the NetMHCpan algorithms for each of the six HLA
class I molecules, HLA-A, B and C in each DRP. IC50 values (nM) indicated the amount of
peptide required to displace 50% of intended or standard peptides specific to a given HLA.
Binding affinity is inversely related to IC50 values such that a smaller IC50 value indicated a
stronger affinity. The variant alloreactive peptides with a cutoff value of IC50 500 nM to the
relevant HLA were included, and designated, presented peptides; and those that had an IC50
50 nM, were termed strongly presented peptides. IC50 values in this range (IC50<500 nM)
were considered relevant in previous studies of HLA-binding [32] and predictive mouse models of CTL response to vaccinia virus epitopes. [33] Further processing and interrogation of
HLA binding in sliding 9-mer windows allowed for affinity sorting and HLA-specific separation along with gene information.

Determining sequence homology between human and CMV derived
HLA bound peptides
The bioinformatic pipeline utilized to interrogate SCT DRPs for HLA bound polymorphic
peptides derived from nsSNP(GVH) in each DRP was extended and refined to interrogate
each SCT DRP for relevant HLA class I bound CMV peptides. The binding of CMV-derived
peptides to specific HLA Class I molecules was the first step towards determining their
sequence homology with human HLA bound peptides. This bioinformatic pipeline is depicted
in Fig 2. The initial step was compilation of the Human CMV-CROSS (Cross-Reactivity of
Open Source Sequences). This is a database of 289 hCMV proteins or variants representative
of the entire known multi-strain inclusive (Merlin, Towne, Toledo and AD169) hCMV proteome sourced from NCBI S1 File (Protein variants had a single or multiple amino acid difference reported for the same protein/CMV gene; Deduplication was performed to remove bias).
[34] The next step was the utilization of previously created patient polymorphic peptide libraries (derived from nsSNP(GVH) in each DRP) for initial feasibility of BLAST protein sequence
alignment analysis. [35] This was followed by a subsequent confirmatory CMV-Human
sequence homology analysis. Sequence homology relied on a match of 6 or more continuous
amino acids in a string of 9 total amino acids (6/6-9/9) by sliding window analysis to identify
sequence overlap between HLA bound 9-mer alloreactive human and hCMV peptides. Next,
HLA Class I binding prediction (NetMHCpan) was performed for the hCMV peptides,
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Fig 2. Bioinformatic pipeline of the alloreactive peptide library comparison with the CMV proteome. A determination of the potential for ProGVHD DRP cross-reactivity upon CMV reactivation correlated with GVHD-tissue specific distribution of peptides & immunogenicity.
https://doi.org/10.1371/journal.pone.0178763.g002

screening the generated hCMV 9-mer peptides for HLA binding affinity across the test patient
population (n = 9).
A specific streamlined bioinformatics application (Table 1) was developed to directly
compare the alloreactive donor-recipient peptide libraries for all the patients (n = 77) to the
HLA bound hCMV peptides by sequence homology; eliminating the need for the Protein
BLAST sequence alignment (6/6 match by 9-mer sliding window analysis using all 9-mers
extracted from each database, DRP peptide library or Human CMV CROSS proteome, prebinding affinity screening). Binding affinity was predicted (NetMHCpan) for all the 70,686
hCMV 9-mer peptides (resulting from the 289 hCMV proteins) to the known 2,915 human
HLA-class I types along with collection of source gene information (hCMV and Human geneids), which were used to sort the peptides for strength of binding affinity. Immunogenicity
screening was then performed to validate CMV-human matched peptides for the presence
of hCMV gene products previously reported as CD8+ T cell targets known to elicit specific
immune responses.

Tissue distribution of cross-reactive peptides
Homologous CMV-Human peptide libraries were compiled for each DRP and the source
genes organized for putative GVHD target tissue-specific distribution analysis using the GTEx
portal for expression data. [37] Each patient with GVHD involving specific tissues (e.g., skin)
had tabulation of those disease-incident tissue-specific alloreactive peptides presented by their
HLA (e.g., 10 skin peptides from 8 genes expressed in the skin) and the remainder GVHD tissue peptides/genes were tabulated as other or nonspecific to the patient’s disease then tallied.
Following criteria were used to assign CMV-Human peptide cross-reactivity potential: 1.
Amino acid sequence homology of 6/6 to 9/9 (9-mers) between CMV and Human HLA
bound peptides 2. IC50 values less than 500 nM for binding to the unique HLA in each DRP
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Table 1. HCMV cross-reactivity potential of 77 SCT DRP from whole exome sequencing data using
sliding window match analysis.
1

289 HCMV protein sequences representative of the HCMV proteome were downloaded from
NCBI by batchentrez utility

2

Downloaded CMV protein sequences were sliced into 9AA peptides and deduplicated, resulting
in a library of 70686 9AA peptides

3

Each of the 70686 9AA peptides were further divided into 2 8AA, 3 7AA and 4 6AA peptides to
form a lookup table for each component peptide (6,7,8) with the one or more 9AA parent
peptide(s) and the associated CMV geneid

4

As a focus on Class I HLA, a list of the 2915 plausible HLA-A/B/C types interrogated by
netmhcpan was compiled

5

IC50 values for all 70686 9AA CMV peptides were precalculated against all 2915 HLA types and
saved in the CROSS database

6

9-mer peptides isolated from ANNOVAR per patient were searched for match with the 9AA CMV
peptide pool
. . . if no match found then each 9-mer was split into 2 8-mers and each searched in the 8AA CMV
peptide pool
. . . if still no match found then each 9-mer was split into 3 7-mers and each searched in the 7AA
CMV peptide pool
. . . if still no match found then each 9-mer was split into 4 6-mers and each searched in the 6AA
CMV peptide pool

7

If any of the above searches found a match, the search was terminated and results for that
patient 9-mer peptide reported

8

Reported 9-mers were linked with geneid (Human & CMV), HLA type, IC50 (Human & CMV),
partial peptide (6/7/8), CMV_peptide (9)

9

Each patient-specific peptide library generated by comparing alloreactive peptides with the
CROSS database were compiled, statistically analyzed (Student’s T-Test) and further screened
for high affinity binding (1/IC50 or an IC50 range of 0–500 nM)

10 Binding strength (IC50<500 nM) of homologous CMV and human peptides to DRP-specific HLA
was compared for pattern analysis
11 Immunogenicity of common CMV gene products as CD8+ T cell targets was screened for
validation on CMV infected patients (n = 30)
12 CMV peptide matches to Human alloreactive peptides underwent multiple rounds of
deduplication to ensure only unique peptide inclusion by both software programming (Excel or
independent coding) and finally by human observation upon final analysis.
13 Gene Tissue Expression (GTEx) data was gathered on CMV infected patients (n = 30) to find
GVHD specific organ incidence
14 Case studies were prepared, 6 patients with CMV before GVHD: 2 acute GVHD, 2 chronic GVHD
and 2 aGVHD + cGVHD.
https://doi.org/10.1371/journal.pone.0178763.t001

(Presented or strongly presented peptides) 3. Human Gene-GVHD Tissue Expression Connection (Patient specific, i.e. skin, GI, etc.)

Patients
CMV reactivation defined as 200 copies of hCMV DNA/μL of plasma was determined by
quantitative polymerase chain reaction. Absolute lymphocyte counts were measured at least
twice weekly following SCT during the first 100 days and at least once weekly out to 6 months
following SCT. Human CMV titers, lymphocyte counts and serum immunosuppressant drug
levels were collected to one year post SCT per MCC-14012 Study. Acute and chronic GVHD
was diagnosed according to Glucksberg and NIH 2005 Consensus clinical criteria, respectively.
Lymphoid recovery patterning was assessed to examine differences among patients with CMV
alone, GVHD alone, both or neither conditions post SCT. Three patterns were observed as
previously described [38]: Pattern A or early (ALC  1 Billion cells/L by Day 45 post SCT),
Pattern B or middle (ALC  0.5 up to <1 Billion cells/L by Day 45 post SCT), and Pattern C
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(ALC <0.5 Billion cells/L by Day 45 post SCT). Student’s T test and Pearson correlation were
utilized for statistical analysis of the alloreactive/CMV peptide data presented. Cox regression
hazard ratio and Kaplan-Meier Survival were utilized for evaluating patient outcomes.

Results
Patient characteristics
Seventy-seven DRPs underwent exome sequencing following SCT, and were assessed by in silico analysis for alloreactivity potential derived from non-synonymous SNPs in the GVHD
direction as previously described. [15] The cohort comprised of 27 MRD and 50 MUD SCT
recipients underwent data collection for retrospective analysis including GVHD occurrence
and hCMV reactivation information S1 Table. Of the 30 patients that experienced hCMV viremia within a median of 29 days from transplant, 26 were hCMV-seropositive or reactivated;
one patient had drug-refractory hCMV infection, and succumbed to it. CMV reactivation was
experienced in conjunction with GVHD in 18 of the 30 patients, 13 of whom experienced
hCMV reactivation prior to GVHD onset. Multiple recurrences of hCMV viremia were experienced in 11 of the 30 patients (2 or more separate reactivation events, 200 copies of hCMV
DNA/μL plasma per event by quantitative polymerase chain reaction).

CMV—Human HLA bound peptide homology
Based on the hypothesis that significant amino acid sequence homology between human- and
viral-derived peptides presented on the same Class I HLA molecules may lead to donor CD8
+ T cell cross reactivity, a bioinformatic pipeline was utilized to assess sequence homology
between the patient’s putative alloreactive peptide library, and hCMV-derived oligopeptides
bound to each recipient’s HLA. Whole exome sequencing of HLA matched SCT donors and
recipients revealed 2,463 ± 603 nsSNPs (mean±SD) with a GVH direction per MRD and
4,287 ± 1154 nsSNPs per MUD recipient (Student’s T-test, p<0.001). Following ANNOVAR
9-mer peptide determination and completion of the sliding window analysis of the resulting 17
amino acid variant oligopeptide resulting from each nsSNP, 43,705 ± 10,938 nonameric potentially alloreactive human peptides were identified per MRD recipient, and 77,025 ± 21,170 per
MUD recipient. These were organized into a library by HLA-specific binding affinity (IC50:
0–50,000 nM). Next, each alloreactive Human 9-mer peptide library was further evaluated for
their degree of match with the 70686 nonamer peptides derived from the hCMV proteome,
utilizing the HLA-specific algorithmic CROSS database. This comparison determined
sequence homology for strings of 6/6 consecutive amino acids between the two sets of
Human and hCMV peptides, and was termed ‘sliding window-match analysis’. This initial
screen yielded an average of 29,659 ± 9039 total peptide matches per MRD patient and
52,910 ± 16122 total peptide matches per MUD patient to the hCMV proteome (Student’s Ttest, p<0.001) following analysis (S1 Fig). The program output reported for each peptide
match, the geneid’s, the HLA, IC50 values (Range: 0–50,000 nM) and complete peptide
sequence, as well as the shared partial peptide for degree of sequence homology.
Upon confirmation that all 77 patient alloreactive peptide-HLA libraries studied had
matches with the hCMV peptide-HLA arrays, the degree of sequence homology in tightly
HLA bound peptides (IC50: 0.01–500 nM) was determined. Following removal of duplicate
peptide sequences, the total CMV-human match (homology) library, yielded an average of 33
peptide matches per MRD patient and 44 peptide matches per MUD patient (Student’s T-test,
p = 0.09), constituting approximately 1% of the total matches reported (Table 2). Considerable
variability was observed in the in silico HLA presentation of human-CMV sequence homologous peptides among the different HLA in the DRP studied (S2 Fig). Analysis of the number of
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Table 2. CMV- Human match analysis per DRP (IC50 <500 nM) by donor type according to continuous amino acid sequence homology (one standard deviation from the mean value).
Mean Relevant
Matches (IC50<500)

Number of
Patients (n)

Sequence
Homology 6/6 (±SD)

Sequence
Homology 7/7 (±SD)

Sequence
Homology 8/8 (±SD)

MRD

27

31 ± 19

2±2

0±1

0±0

33 ± 20

MUD

50

40 ± 33

3±6

1±2

0±1

44 ± 39

Overall

77

37 ± 29

3±5

1±2

0±1

40 ± 34

0.12

0.09

0.07

0.38

0.09

Student’s T-test (p < .05)

Sequence
Total 6/6 to 9/
Homology 9/9 (±SD)
9 (±SD)

https://doi.org/10.1371/journal.pone.0178763.t002

Human—CMV matches with IC50<500 nM yielded a lack of association between how common different HLA molecules are within a given population and the overall average or peak
number of matches per HLA. The most common HLA-A (02:01) to our patient population
was outside the top ten molecules to have the highest average or peak number of Human—
CMV matches. The homologous sequence information per patient’s peptide library following
high affinity match analysis (IC50<500) was compiled into S2 File; this includes an immunogenicity sorting performed for hCMV reactivating patients. Considering the degree of
sequence homology present between hCMV and human peptides bound to HLA class I molecules in specific DRP, each MRD DRP on average had 31, 2, 0 and 0 relevant nonameric
CMV-Human peptide matches with 6/6, 7/7, 8/8 and 9/9 sequence homology respectively
(Table 2). Also each MUD DRP on average had 40, 3, 1, and 0 peptide matches with 6/6–9/9
sequence homology respectively. As expected from the donor type SNP differences, relevant
alloreactive peptide differences, and total peptide matches with hCMV, MUD DRPs exhibited
a trend for a higher number of hCMV matched peptides than MRD DRPs by peptide sequence
homology differences (6/6-9/9 matching; student’s T-test, p = 0.07–0.38 respectively). To
determine the correlation of the number of high affinity CMV-Human matches (IC50<500
nM) with sequence homology >6/6 amino acids in 76/77 patients, these were plotted against
the pool of total alloreactive peptides per patient (Fig 3). Notably, MUD DRPs post screening
(IC50<500 nM) exhibited a mean of 6,545 ± 2689 alloreactive peptides per patient which was
significantly greater than the 4,522 ± 1915 mean alloreactive peptides per MRD DRPs (Student’s T-test, p<0.001) prior to interrogating for matches to the hCMV proteome, with a
trend for a higher prevalence of CMV-Human matches in the MUD recipients. These results
indicate that there exists a pool of homologous-CMV-derived peptides, which may be presented by the recipient HLA.

Potential immunogenicity of the hCMV peptides presented on recipient
HLA
To compare the sequence homology analysis results and determine the presence of previously
validated immunogenic hCMV peptides, [36] the specific hCMV peptide sequences and the
proteins of origin were reviewed (Table 3). Twelve of the 13 patients with hCMV reactivation
before GVHD onset exhibited one or more immunogenic hCMV peptide matches, derived
from CMV protein previously shown to elicit a hCMV-specific T-cell response targeting the
listed source genes. The remaining patient expressed CMV—Human peptide-matches derived
from proteins specific to the patient’s affected GVHD tissue, which had not previously been
reported in other studies. The analysis revealed multiple CMV-Human peptide matches that
were, immunogenic (IC50<500 nM) and expressed in a GVHD-affected tissue-specific manner. Further, the binding affinity (reflected by the IC50 values) of hCMV peptides when plotted against the IC50 values of the alloreactive Human peptides S3 Fig, demonstrated a wide
range of values, indicating the potential for varying degrees of cross reactivity. This analysis
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Fig 3. CMV+GVHD cross reactivity potential. Patient-specific peak CMV peptide matches intersecting peak alloreactive peptides (IC50<500 nM) as
a cross-reactivity potential stratified by donor type contained within each DRP alloreactive peptide library.
https://doi.org/10.1371/journal.pone.0178763.g003

illustrates the magnitude of overlap in peptide sequence between the two sources of HLA presented peptides.

Tissue expression of cross-reactive human peptides
In order to study the GVHD tissue-specific expression of the hCMV peptides matched to
human alloreactive peptides (Table 3), gene expression data organized in a tissue specific manner was obtained from the GTEx Portal of the Broad Institute of MIT and Harvard (Version
6). [37] Gene expression data for all CMV-Human peptide matches in the 30 hCMV reactivating/de novo infected patients was compiled (median minimum threshold of expression: 10
reads/kilobase of transcript/million mapped reads), specifically focusing on GVHD target tissues including: skin, GI, liver, lung, and others (vagina, muscle, adipose and salivary gland). A
focused analysis of GVHD tissue gene expression in conjunction with actual GVHD occurrence was performed on 18 patients with GVHD and hCMV reactivation, and showed that
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Table 3. GVHD tissue-specific immunogenic CMV peptide matches, CMV reactivation before GVHD patients. Patient-specific process of cross comparison along with the source genes, IC50 values to indicate inverse binding affinity and GVHD organ specific tissue involvement. *Note: Twelve patients with
CMV reactivation/infection before GVHD onset exhibited previously identified immunogenic CMV peptide matches with gene expression specific to the tissues
affected by GVHD (above); The filter of immunogenicity provides a connection to T cell reactivity shown in vitro to the listed CMV genes in a separate patient
population [36]; Patient 79 with muscle/fascia GVHD showed no muscle-specific previously known immunogenic CMV peptide matches but still had three relevant CMV peptide matches expressed in the skeletal muscle (not shown); Tissues in parentheses were also affected by GVHD but without immunogenic
matches/expression by patient; Patients 67 and 71 experienced de novo CMV infection; All 13 patients exhibited multiple CMV peptide matches with unknown
immunogenicity.
Patient
10*

HLA

Human Gene IC50 Value DRP Peptide

HLA-B40:01

TSPYL1

12

SETVALPPL

QENSETVAL

23

UL86

HLA-B40:01

HDAC7

27

EEVEAVTAL

AEREAVTAL

20

UL49

HLA-B08:01

APEH

487

NRRSALYSV

MWKNRRSAL

11

UL37

WKNRRSALL

274

UL37

HLA-C03:04

IL22RA1

16

IVHPTPTPL

SSTPTPTPL

42

UL82

HLA-A02:01

TECR

28

ALFSLVVFT

YLFSLVVLV

3

US3

LVYLFSLVV

442

US3

HLA-C03:04

WNK1

41

ITAAATAPV

TTAAATATV

199

UL105

HLA-A68:02

PPP1R15A

149

SSAAAAAAL

TAAAAAAAA

58

IRS1,
TRS1

HLA-A68:02

ATAAAAAAA

59

IRS1,
TRS1

HLA-B08:01
27*

HLA-A02:01
45*

HLA-A68:02

DAAAAAAPT

286

IRS1

HLA-A68:02

SVSSSAAAA

376

UL105

HLA-A68:02

SASAAAAAA

469

UL105

HLA-A68:02

DATAAAAAA

470

IRS1,
TRS1

HLA-A68:02

MUC21

106

ESSTTSSGA

TTYTTSSGA

24

UL86

YTTSSGAKI

140

UL86

AAAAAAAGA TAAAAAAAA

58

IRS1,
TRS1

HLA-A68:02

ATAAAAAAA

59

IRS1,
TRS1

HLA-A68:02
HLA-A68:02

47*

48*
67*

CMV Peptide IC50 Value CMV Gene

HOXD13

352

HLA-A68:02

DAAAAAAPT

286

IRS1

HLA-A68:02

SASAAAAAA

469

UL105

HLA-A68:02

DATAAAAAA

470

IRS1,
TRS1

GVHD Organ with Target Gene
Expression
Skin

Skin

Skin & Vagina

Vagina

HLA-B07:05

MUC17

52

TPVSHTLVA

TPVSHTQPL

8

UL150

HLA-A30:02

CARS2

343

SPASLSSLY

YFDSLSSLY

173

UL29,
UL28

HLA-A31:01

PLXND1

200

LFVFCTKSR

NLFVFCTER

58

UL34

GI (Skin & Liver)

HLA-A31:01

PLXND1

307

VALFVFCTK
VLLLALLLL

209

US29

GI, Lung (Skin)

ASLLTAVRR

68

IRS1,
TRS1

GI, Liver (Skin)
GI

HLA-A02:01

FGFR4

20

RLLLALLGV

HLA-A02:01

FGFR4

165

LLLALLGVL

68*

HLA-A31:01

ALCAM

188

TYTLTAVRR

70*

HLA-C07:02

LCN2

122

SYPGLPSYL

MRPGLPSYL

50

UL75

HLA-B35:01

SERPINB4

97

EAAAATAVL

CAAAAATAA

393

UL105

HLA-A03:01

FYCO1

488

RASLKRLVK

STLKRLVKK

83

UL69

GI

(Continued)
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Table 3. (Continued)
Patient

HLA

71*

HLA-C03:03

Human Gene IC50 Value DRP Peptide
PPP1R15A

19

SSAAAAAAL

CMV Peptide IC50 Value CMV Gene
AAAAAAPTV

48

IRS1,
TRS1

HLA-C03:03

AAAAAAAAA

343

IRS1,
TRS1

HLA-C03:03

TAAAAAAAA

389

IRS1,
TRS1

HLA-C03:03

SASAAAAAA

421

UL105

HLA-A30:02

CARS2

343

SPASLSSLY

YFDSLSSLY

173

UL29,
UL28

76*

HLA-A03:01

ZZEF1

119

SVLSELLKK

SVLSELLNK

91

UL54

HLA-B27:05

MUC4

414

TRHATSLPV

YQLRHATSL

473

US29

84*

HLA-A02:01

FGFR4

20

RLLLALLGV

VLLLALLLL

209

US29

HLA-A02:01

FGFR4

165

LLLALLGVL

HLA-C02:02

MUC17

270

TSMPVSTTV

ISYPVSTTV

215

UL75

HLA-B27:05

MUC4

414

TRHATSLPV

YQLRHATSL

473

US29

HLA-A02:01

PELP1

78

LLALLLAPT

LLALLLLEL

38

US29

VLLLALLLL

209

US29

145

UL86

90*

HLA-A02:01
HLA-A02:01

AHSA1

321

KTLFLAVQV

ELFLAVQFV

HLA-C03:03

TCF7L1

107

AAASSSGQM

AAASSSSAV

27

UL48

IAAASSSSA

220

UL48

HLA-C03:03
HLA-A03:02

ZZEF1

325

SVLSELLKK

SVLSELLNK

185

UL54

HLA-C03:03

PLEKHA6

385

AASSSLRRL

FGGAASSSL

71

UL122

GVHD Organ with Target Gene
Expression
Skin

GI
GI (Skin)

Skin & GI

GI

https://doi.org/10.1371/journal.pone.0178763.t003

18/18 patients had expression of hCMV-matched alloreactive peptides (IC50<500 nM) with
10 RPKM tissue-specific gene expression (Table 4). As depicted, combining both match data
and gene expression data, a cross reactivity profile was created for the hCMV infected subset
of patients to include: match number, discrete numbers of peptides (Human and CMV), gene
count, immunogenic hCMV genes, and tissue specific GVHD peptides or genes. These data
points taken together comprise a predictive case for potential alloreactive trigger following
hCMV infection if human and CMV peptide libraries possess enough peptide sequence
homology that may be derived from whole exome sequencing of transplant donors and recipients using this analytic approach.

Clinical correlations of CMV reactivation with GVHD
In this cohort hCMV reactivation following SCT, was associated with poorer survival (n = 46,
Log Rank: 4.5, p = 0.03, Hazard ratio: 2.31, p = 0.04) when adjusting for hCMV reactivation by
donor or recipient seropositivity S4 Fig, consistent with the findings of a recent CIBMTR analysis. [2] Further we observed a trend of poor survival among CMV seropositive DRPs that
experienced hCMV reactivation along with GVHD S5 Fig (n = 46, Log Rank: 3.04, p = 0.08,
Hazard ratio: 2.02, p = 0.09). To determine whether there was any association between onset
of hCMV reactivation and GVHD, we evaluated lymphocyte growth kinetics and large variations in calcineurin inhibitor levels as possible triggers of GVHD occurrence in the above referenced patients (Table 4). Lymphoid recovery patterns were examined among these patients
with early lymphocytosis seen in patients with CMV viremia S6 Fig. GVHD was also examined
for association with lymphoid recovery rate and magnitude along with CMV reactivation.
CMV reactivation + GVHD patients did have a trend for more frequent occurrence of earlier
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X

X

X

X

X

X

X

https://doi.org/10.1371/journal.pone.0178763.t004

81

X

X

73

38

X

X

X

34

X

X

X

X

X

41

X

X

90*

X

84*

79*

76*

71*

X

X

68*

70*

X

X

48*

67*

X

X

X

27*

45*

Peptides**

10

5

12

32

38

39

21

39

10

29

25

10

28

24

21

17

43

58

17

5

12

47

57

56

25

49

11

55

28

10

43

25

23

45

64

72

Lung Vaginal Muscle Human Matches

GVHD Incidence

GI Liver

X

X

10*

47*

Skin

n = 18

Patients

10

5

11

41

47

43

21

41

11

39

22

10

36

21

22

26

55

58

1

6

8

8

1

2

2

3

5

7

7

10

CMV Skin

4

2

5

17

7

5

9

7

8

11

6

GI

2

2

5

Liver

9

9

3

Lung Vaginal Muscle

GVHD Tissue Specific Peptides (IC50: <500
nM)

6

5

11

30

32

36

18

28

10

28

21

10

24

21

20

15

39

47

0

0

2

6

12

7

4

7

4

8

5

2

4

5

5

5

9

10

6

4

11

29

31

27

14

26

10

30

21

10

24

18

19

15

35

35

1

6

7

7

1

2

2

3

4

6

7

8

Human Immunogenic CMV CMV Skin

Genes

2

2

4

16

6

5

8

7

7

9

6

GI

1

2

4

Liver

7

8

2

Lung Vaginal Muscle

GVHD Tissue Genes (RPKM: >10)

Table 4. Human-CMV short sequence homology in GVHD tissue specific peptide and gene distribution from GTEx analysis (n = 18). GVHD incidence denotes the specific
organs affected in each patient; Peptides, lists the number of unique peptide-HLA complexes matched between human and CMV peptide library; the column, Genes lists the source
genes for the aforementioned peptides; GVHD tissue specific peptides lists the number of peptides which bind HLA with an IC50 <500nM, and are expressed in tissues affected by
GVHD; GVHD tissue gene expression denotes the number of genes expressed at an RPKM >10 corresponding to the GVHD tissue specific peptides. Note: *- All patients with an asterisk following their numeric representation experienced CMV reactivation prior to GVHD (except Patients 67 and 71, de novo CMV infected) and patients without an asterisk experienced
GVHD prior to CMV reactivation. **- human peptides may have overlapping areas of homology yielding a higher number of matches. Immunogenic CMV genes in this context refer to
the genes associated with HCMV ORF-specific CD8+ T memory cell responses measured in frequency among CMV seropositive patients previously [36].
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and larger magnitude lymphoid recovery patterns compared with GVHD alone, CMV alone
or the patients with neither. There was however no significant difference in survival between
these patient groups S7 Fig. Importantly in the patients with an observed association between
CMV reactivation, lymphocytosis and GVHD onset, the T cells were found to be donorderived DNA by chimerism analysis in most of our patients.
In the 30 hCMV-reactivating patients examined S2 File, reactivation events were often
coincident with GVHD onset and associated with preceding lymphocytosis, suggesting an
alloreactive cellular immune response S8 Fig (Panels A, B and C). Acute GVHD onset following hCMV reactivation was seen in 7 of the 13 patients experiencing hCMV reactivation before
GVHD; 3 of these patients developed grade IV gastrointestinal GVHD (2 steroid refractory)
which was fatal in all cases. As seen in figure S8 Fig (Panel A), with acute GVHD in patients 47
and 68, there was evidence of hCMV reactivation events (top graph) that preceded rapid onset
lymphocytosis (middle graph) and often occurred with stable CNI or immunosuppression levels (bottom graph), indicating a potential hCMV-GVHD relationship. Patients 47 and 68 with
acute GI GVHD had an average of 16.5 ± 9.2 matches (±SD) derived from 15.5 ± 7.8 human
peptides. Patient 68 also exhibited skin and liver GVHD. When considering the percentage of
genes with GVHD-tissue specific expression on average, in these two patients 87.5 ± 17.7%
peptides were derived from GI tract specific alloreactive-hCMV matched genes (primary
GVHD organ).
Patients depicted in S8 Fig (Panel B, patients 10 and 27) exhibited the more stable or gradual hCMV reactivation effects seen in chronic GVHD, where lower or less frequent elevations
in hCMV titers may still elicit lymphocyte growth, albeit at a slower rate, probably accounting
for the observed difference in outcomes between patients with symptoms of only acute GVHD
or chronic GVHD. Patients 10 and 27 with Chronic Skin GVHD had a mean of 68 ± 5.7
matches (±SD) derived from 50.5 ± 10.6 human peptides. These two patients exhibited a lower
percentage of GVHD-tissue specific gene expression on average when considering all potential
GVHD genes identified, in this instance skin gene expression amounted to 51.9 ± 2.7%.
The final S8 Fig group (Panel C, patients 71 and 84) exhibited symptoms of both acute and
chronic GVHD at different times post transplant with differing disease patterns according
to the GVHD tissues involved (i.e., acute skin or GI vs chronic skin or GI GVHD may be
defined/graded differently), but patient 84’s lower grade cyclical reactivation events altered the
lymphocyte growth pattern towards a recurring waveform pattern, with peaks and troughs of
lymphocytes over time. Patients 71 and 84 exhibiting both acute and chronic GVHD had a
mean of 40 ± 21.2 matches (±SD) derived from 25 ± 5.7 human peptides. Patient 84 also exhibited GI and liver GVHD. Patients 71 and 84 also exhibited lower GVHD-tissue specific gene
expression on average when considering all potential GVHD genes identified, Skin,or GI (primary organs): 44.3 ± 27.3%. There were 3 patients who developed recipient-derived T cell chimerism following CMV reactivation and lymphocytosis (patients 2, 7 and 28), suggesting
expansion of recipient derived T cell clones in response to CMV reactivation. These three
patients were all CMV sero positive with CMV + donors. These variable dynamics of hCMV
reactivation and GVHD onset demonstrate the complexity involved in analyzing the relationship between ongoing immunosuppression in the setting of multiple sets of potentially cross
reactive antigens by affected organ system being presented to a reconstituting donor-derived
immune system.

Discussion
CMV reactivation is a frequent complication of allografting, requiring frequent monitoring
and associated with an increased risk of treatment related mortality, primarily in its own right,
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but also because it is frequently associated with GVHD. [12] Therapy and effective prophylaxis
involve the use of toxic drugs and monitoring for reactivation is not straightforward. The ability to identify patients at risk of developing alloreactive complications from hCMV reactivation will therefore be a useful adjunct to the supportive care of transplant recipients, as well
as an important step forward in understanding virus-induced-alloreactivity. In this paper a
computational algorithm that identifies hCMV peptides homologous to human alloreactive
peptides is described. This determination required three steps, whole exome sequencing of
transplant donors and recipients, followed by in silico determination of the patient specific
class I HLA binding of the oligopeptides resulting from the nsSNP in the exome and finally a
comparison of these alloreactive peptide sequences with those of hCMV peptides predicted to
bind the same HLA molecules. This algorithm identifies a number of hCMV peptides which
bind the same HLA as human peptides with a similar range of binding affinities and also demonstrate a degree of sequence homology with the human peptides. We hypothesize that these
peptides may potentially be cross-presented to donor T cells.
To understand how this may impact GVHD pathophysiology, consider a T cell clone
(TCCMV), which recognizes an hCMV peptide-HLA complex, is activated by hCMV viremia.
The T cell receptor of this clone may also recognize a human alloreactive peptide with
sequence homology to the hCMV peptide and bound to the same HLA molecule. Even if it
does so weakly, tissue damage may be initiated and GVHD ensue. This process can work in
reverse as well, a T cell clone with high affinity for alloreactive peptides (TCmHA), which only
binds the hCMV peptide-HLA complex weakly may be ‘set-off’ by a hCMV reactivation event,
again leading to down-stream GVHD. This general principle may hold true for other virus
derived peptides.
A mathematical model utilizing matrices has been developed to understand aggregate T cell
responses to many mHA-HLA complexes the donor T cells may encounter in the recipient
milieu. [39] The simplifying notion underlying this model is that each donor T cell interacts
with a single recipient HLA-bound antigen, therefore an identity matrix may be used to calculate the resulting T cell response. This model requires that the antigens occupy the matrix
operator (MAPO) and T cell vector gets transformed by the operator (Table 5).
In the above simplified matrix T cell clone (Table 5), TC1 interacts with mHA1, and so on.
The 1 in the cells means that the T cells recognize that antigen and responds, and 0 means
absence of recognition, this can also be understood as probability of TCR binding to the peptide-HLA complex. In reality, the TCR-Ag-HLA interactions are not likely to be quite so simple. An important clue to this is the observation that antigen-HLA binding affinities, reported
in this paper as IC50, do not take on discrete values of 0 or 1 (binding or no binding); instead
there is a continuum of IC50 values. So in the case of cross-reactive antigens, a hCMV derived
antigen binds the same HLA molecule and may interact with the T cell receptor, albeit with a
different binding affinity. This implies that each TCR might interact with multiple antigens
with different affinity, thus the 0 in the matrix above may in reality be replaced with a series of
numbers between 0 and 1. These cross-reactive antigens may augment the T cell response to
Table 5. Matrix depicting the T cell clonal interaction with mHA-HLA.
MAPO
mHA1 HLA

mHA2 HLA

mHAn HLA

TC1

1

0

0

TC2

0

1

0

TCn

0

0

1

https://doi.org/10.1371/journal.pone.0178763.t005
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Table 6. Matrix depicting T cell clonal cross-reactivity between CMVp-HLA and mHA-HLA. *-indicates
response of the alloreactive T cell clone to a viral pathogen peptide,bound to the same HLA as the mHA and
vice versa. For example, TC1 recognizes, mHA1 HLA + CMVp2HLA, TC1CMV recognizes, mHA1 HLA
+ CMVp1 HLA, and so on.
MAPO
TC1

mHA1-HLA

(CMVp1-HLA)

mHA2-HLA

(CMVp2-HLA)

1

0.2*

0

0

TC2

0

0

1

0.3

TC1CMV

0.3*

1

0

0

TC2CMV

0

0

0.1*

1

https://doi.org/10.1371/journal.pone.0178763.t006

the primary target antigens, as shown in the matrix below where cross reactivity is depicted
(Table 6).
The notion of T cell receptor (TCR) cross reactivity presented here also merits further
discussion. An argument may be made that mHA that do not share an entire sequence are
unlikely to elicit a response from relevant TCR. However this argument assumes a rigid interaction between the TCR and the mHA-HLA complex. In reality these interactions are likely to
be elastic in nature, as can be inferred from the continuum of values that the CMV peptide/
mHA-HLA IC50s demonstrate. In a rigid frame work one will likely observe discrete binding
affinity value sets. Such ‘elasticity’ in TCR recognition has previously been demonstrated in
the context of HLA-B35:01 bound HIV-1 derived Nef epitope VY8. In this study, patient
derived CD8+ T cell clones recognized index peptides despite substitution in the AA residues
along the peptides, demonstrating unique cross reactivity ‘footprints’ for individual T cell
clones. [40,41] The counter argument of multiple T cell clones recognizing a single antigen has
also been studied in the context of tumor antigen HLA-A:0201/NY-ESO-1 specific CD8+ T
cell clones, where multiple T cell clones with relatively restricted TRB V and J segment usage
were identified. These T cell clones were equally efficient and dependent on recognition of the
central peptide residues for activity. [42] Similar findings have been reported for melanoma
tumor infiltrating CD8+ T cells which recognize variants of HLA-A2 bound MART-1 antigen
variants. [43] Other models of T cell cross reactivity have also been reported in the literature
for TCR recognition, such as, widely degenerate recognition of unrelated peptides in peptideMHC complexes exhibiting docking geometry diversity and CDR Loop displacement. [16,44–
46] Alternatively, TCR recognition of only closely related peptides to original pathogenderived peptides with the same docking geometry of binding and similar CDR3 displacement
patterns has been proposed more recently. [47] Another consideration is the differential effect
of binding affinity and stability of CMV peptide/mHA—HLA interactions influenced by
enhanced antigen availability by either greater proteolytic activity [48] or related to higher tissue expression levels. [49–51] Taken together these lines of evidence suggest that TCR cross
reactivity, and stimulation of alloreactivity is certainly possible in the context of the same HLA
molecules presenting both CMV and alloreactive human peptides with sequence homology. It
is however important to recognize that this mechanism most likely only contributes to the initiation of GVHD in some patients, with more conventional alloreactive T cell responses occurring in the face of tissue injury and systemic inflammation being responsible for GVHD in
most cases. [52] While the in silico analysis for hCMV + alloreactivity potential reveals a large
body of antigens which may influence clinical outcomes. However, there are caveats to be considered in developing this peptide analysis pipeline. First, the process of creating the CMV
CROSS database included some variant forms of the hCMV proteins known to have differing
amino acid lengths that may allow for duplicates, which were accounted for during multiple
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processes of deduplication. However the slight differences to the variant forms of the proteins
reported in the NCBI database may generate a few more peptide possibilities than may be
realistic but would allow for strain differences of the human peptide matches during exome
sequencing.
An interesting observation among alloreactive or hCMV peptides was where human genes
and hCMV immunogenic genes were shared among multiple patients with many of each gene
or peptide involved being common in our cohort, often with the same HLA specificity and
predicted binding affinity S2 File. Epitope spreading is another phenomenon, that may be
exemplified by donor lymphocytes and antigen presenting cells encountering either hCMV or
recipient alloreactive peptides released upon organ damage that may be processed and presented in an HLA restricted manner and elicit an immune response. CMV has evolved in parallel with the human genome over hundreds of millions of years, potentially exchanging
genetic information from virus and human randomly with each latent infection, selecting primarily for immune evasion. [53] This phenomenon shields hCMV from immune response but
also exposes endogenous antigens from recipient cells simultaneously with hCMV antigens to
donor immune surveillance during organ damage from lytic reactivation in athymic adults.
[54] This form of epitope spreading, developing T cell antigenic experience, affects overall
immune responses and may account for the robust CD8+ T cell response to hCMV infection
in otherwise healthy individuals (10% of the entire T cell compartment) that inflates with age.
[36] In addition, the primarily memory T cell response to hCMV accounts for the sharp
responses to various hCMV antigens upon reactivation, which may be as great as 50 fold the
strength of a naïve T cell response during primary infection. [19] Recently, reduced TCR repertoire diversity in naïve T cells has been reported in patients who have CMV reactivation and
GVHD following MUD SCT. The authors evaluated repertoire deficiencies by comparing
patient samples with reference and found that patients who had CMV reactivation, with or
without GVHD had greater ‘holes’ in the repertoire, suggesting that an oligoclonal population
of cross reactive T cells clones may lead to immune dysregulation. [55] Strong CD8+ and CD4
+ response to soluble recombinant hCMV antigen has been demonstrated in the past. [56]
This may be related to epitope spreading in post-transplant viral immunity, as has already
been discovered in Multiple Sclerosis and in other autoimmune disorders. [24,57,58]
Nevertheless, GVHD is a condition that is primarily dependent on the presence of an adequate
alloreactive stimulus, the abrogation of which would mitigate GVHD regardless of CMV reactivation. This may be observed in recipients of T cell depleted transplants, including some of
the patients reported here. Further, when considering the opportunity for hCMV to catalytically trigger GVHD apart from the potential method we propose here, we must note that
hCMV is the largest of the herpesvirus family with a 235 kb DNA genome capable of encoding
more than 200 potential protein products [59] and second the near ubiquity of cells it is capable of infecting in man, including parenchymal and connective tissue cells of virtually any
organ along with various hematopoietic cell types. [60]
In conclusion, this paper reports sequence homology in HLA bound peptide antigens of
hCMV and human origin. Given the distribution of human peptides in various tissues, and
their involvement with GVHD in the patients examined, we posit that hCMV derived peptides
may influence the development of GVHD in patients who develop hCMV reactivation following SCT These findings support the use of more aggressive antiviral strategies for preventing
hCMV reactivation in patients undergoing allografting and argue against the use of simply
monitoring as the major therapeutic strategy. We endeavor in the future to understand the
supporting CD4+ T cell hCMV protective dynamics involved by interrogating HLA class II
peptides, (1) looking at potential influences of human CMV mimicry and unraveling the
potential GVHD/CMV cross-reactivity/Auto-immune relationship further. [13,18,24,61–65]
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Supporting information
S1 File. Appendix A. CMV CROSS database tools excel spreadsheet.
• Sheet 1. CMV proteome—NCBI accessions: hCMV/HHV5
• Sheet 2. CMV immunogenic protein—CD8+ list from Ref. #36.
(XLSX)
S2 File. Appendix B. Match analysis excel spreadsheet.
• Sheet 1. Raw CMV match algorithm results—pre-IC50 screening
• Sheet 2. Match analysis summary—total peptide # by patient
• Sheet 3. Match analysis peptides—screened, sorted pt. peptides
• Sheet 4. All CMV case studies, tables, and figures
• Sheet 5. Peptide-HLA binding patterns sorted by CMV+GVH
• Sheet 6. Exome dataset—retrospective, de-identified info.
(XLSX)
S1 Fig. MUD vs MRD total human—CMV matches. Total number of Human—CMV
sequence homologous peptides without binding affinity filtering by IC50 values for TCR relevance. Range of IC50 values: 0.01–50000 nM. Averaged number of total matches for MRD
DRP (Left, Blue) versus MUD DRP (Right, Green) were displayed above the graph to indicate
the observed difference of CMV peptide matches to alloreactive peptides prior to screening by
donor type.
(TIFF)
S2 Fig. Match analysis by HLA locus. Average number of HLA bound human—CMV
sequence homologous peptides ordered by number of peptides presented by HLA locus.
Descending order of average matches per HLA (>5 matches per HLA as threshold). Error bars
indicated where HLA molecules were shared by more than one DRP and matches averaged.
(TIF)
S3 Fig. Human vs CMV binding affinity patterning to DRP-shared HLA. Binding affinity
differences indicated by inverse IC50 values from matched human and CMV peptides bound
to the same HLA. Each data point represents the intersection of a matched peptide bound to
an HLA class I molecule (CMV!Human). These peptides may be cross reactive, with varying
degrees of T cell cross reactivity potential for alloreactivity trigger to ensue (towards the origin
on the human peptide axis being the greatest).
(TIF)
S4 Fig. Survival by CMV incidence accounting for reactivation. GVHD-independent effects
of CMV post SCT in CMV seropositive DRP (n = 46).
(TIF)
S5 Fig. Survival by CMV & GVHD incidence accounting for reactivation. Cumulative
effects of CMV viremia + GVHD post SCT in CMV-seropositive DRP (n = 46).
(TIF)
S6 Fig. Lymphoid recovery pattern by CMV+GVHD status. (Top) Lymphoid Recovery Patterns by ALC value achieved by Day 45 post SCT. Pattern A showed early lymphoid recovery
(Patient 2), Pattern B showed a medium time to lymphoid recovery (Patient 48) and Pattern C

PLOS ONE | https://doi.org/10.1371/journal.pone.0178763 August 11, 2017

17 / 23

Human-CMV HLA bound peptide sequence homology

showed late or very low lymphoid recovery (Patient 16). Trendlines indicated the fit to the
logistic pattern previously observed. (Bottom) Lymphoid Recovery Patterns by CMV+GVHD
Status (n = 77): CMV Reactivation triggers Lymphocytosis that may influence GVHD onset.
Fisher’s Exact Chi Square compared CMV + GVHD groups with lymphoid recovery patterns
as shown.
(TIF)
S7 Fig. Cumulative survival by CMV & GVHD incidence. CMV reactivation with or without
GVHD onset affects the survival negatively compared to the protective GVHD effect.
(TIFF)
S8 Fig. GVHD patient case studies with coincident lymphocytosis and prior CMV reactivation, split by onset/ progression type. (A) CMV-reactivation course with acute GVHD onset
and progression: Patients 47 and 68. Patient 47, grade IV GVHD of the GI tract; patient 68,steroid refractory grade IV GI tract GVHD, skin and liver. Both patients showed signs of CMV
reactivation and bursts of lymphocytosis prior to GVHD onset during stable immunosuppression (TAC, Tacrolimus; SIR, Sirolimus; Cyclosporin) as measured by serum levels or following
taper. (B) CMV-reactivation with chronic GVHD onset: Patients 10 and 27. Patient 10 had
CMV reactivation prior to a gradual lymphocyte proliferation during stable immunosuppression levels (TAC, Tacrolimus) and eventually developed relapsed malignancy. Patient 27
exhibited a CMV reactivation event prior to lymphocytosis at stable tacrolimus levels, and
had mainly skin and oral GVHD. (C) CMV reactivation/de novo infection in patients with
aGVHD + cGVHD: Patients 71 (new, continuous infection for 200+ days) and 84 (reactivation). Patient 71 showed poor lymphoid recovery, continuous CMV viremia and eventual
relapsed malignancy, also developed aGVHD of the skin grade I and also developed mild
cGVHD of skin. Patient 84 exhibited lymphocytosis following CMV reactivation events and
eventually developed acute recurrent gut and skin grade IV GVHD. This patient also developed moderate cGVHD of gut, skin and liver. Both patients received tacrolimus.
(TIF)
S1 Table. Patient characteristics.
(TIF)
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